Key Early-Stage Lung Cancer Trials: An Interview With Jonathan David Spicer

At the 2024 STS Annual Meeting, CTSNet Editor in Chief Joel Dunning and CTSNet senior editors set out to interview the most knowledgeable CT surgeons from around the world. Stay tuned for more interviews from the meeting.



CTSNet Senior Editor Mara Antonoff spoke with Dr. Jonathan David Spicer, a thoracic surgeon at McGill University in Montreal, Canada, about the updated surgical outcomes of the KEYNOTE-671 trial presented at the 2024 STS Annual Meeting. The trial is primarily a comparison of perioperative chemotherapy versus chemotherapy alone for early-stage non-small cell lung cancer and is significant as the first study to show overall survival in the context of neoadjuvant chemo-immunotherapy.

Disclaimer

The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.